Despite the set back in advanced gastric cancer, the company announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab (DKN-01) in combination with bevacizumab and ...
The company's financial position has weakened, with cash and cash equivalents dwindling to $198.3 million at the end of September from $464.7 million at the end of the previous year. Over the course ...
Walgreens Boots Alliance (WBA) shares declined during Tuesday's trading session following a Department of Justice lawsuit alleging that the pharmacy chain knowingly dispensed millions of illegal ...